SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial - Summary - MDSpire

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

  • By

  • Lauren Averett Byers

  • Byoung Chul Cho

  • Alissa J. Cooper

  • Anne C. Chiang

  • Ji-Youn Han

  • Muhammad Furqan

  • Afshin Dowlati

  • Daniel Morgensztern

  • Kyriakos P. Papadopoulos

  • Noura J. Choudhury

  • María Vieito

  • Jair Bar

  • Joo-Hang Kim

  • Wallace Akerley

  • Tae Min Kim

  • Young-Chul Kim

  • Luis Paz-Ares

  • Myung-Ju Ahn

  • Hiroshi Yokouchi

  • Darius Meiman

  • Wijith Munasinghe

  • Oluwadamilola Ogunyankin

  • Nadine Jahchan

  • Song Wang

  • Cristiano Ferlini

  • Randy R. Robinson

  • Frederick J. Kohlhapp

  • Tammy Palenski

  • Guillermo Rivell

  • Pooja Hingorani

  • Sreenivasa Chandana

  • June 1, 2026

  • 0 min

Share

Objective:

To evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ABBV-706 in patients with relapsed/refractory solid tumors, particularly those with relapsed/refractory small cell lung cancer (SCLC) and other advanced solid tumors.

Key Findings:
  • ABBV-706 monotherapy demonstrated a manageable safety profile.
  • The overall response rate (ORR) was 43.8%, with 60.9% in patients with relapsed/refractory SCLC, indicating a potential improvement over existing therapies.
Interpretation:

Preliminary results indicate promising antitumor activity of ABBV-706 in patients with relapsed/refractory SCLC, suggesting further investigation is warranted.

Limitations:
  • The study is ongoing, and results are preliminary.
  • The sample size for specific cohorts may limit the generalizability of findings, and potential biases should be considered.
Conclusion:

ABBV-706 shows potential as a treatment option for patients with relapsed/refractory SCLC, warranting further studies to confirm these findings.

Original Source(s)

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

  • by Lauren Averett Byers, Byoung Chul Cho, Alissa J. Cooper, Anne C. Chiang, Ji-Youn Han, Muhammad Furqan, Afshin Dowlati, Daniel Morgensztern, Kyriakos P. Papadopoulos, Noura J. Choudhury, María Vieito, Jair Bar, Joo-Hang Kim, Wallace Akerley, Tae Min Kim, Young-Chul Kim, Luis Paz-Ares, Myung-Ju Ahn, Hiroshi Yokouchi, Darius Meiman, Wijith Munasinghe, Oluwadamilola Ogunyankin, Nadine Jahchan, Song Wang, Cristiano Ferlini, Randy R. Robinson, Frederick J. Kohlhapp, Tammy Palenski, Guillermo Rivell, Pooja Hingorani, Sreenivasa Chandana

  • June 1, 2026

Related Content

Treatment of parotid gland oncocytoma: a case report from a radiation oncologist’s perspective

Four-dimensional computed tomography ventilation imaging-guided radiotherapy planning in different techniques for lung cancer

Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer: A Randomized